A Prospective Multicenter Clinical Performance Evaluation of the C-CGM System
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background: Continuous glucose monitors (CGMs) have had a significant impact on the management of diabetes mellitus. We present the results of a multinational evaluation of the Cascade CGM (“C-CGM”) over 14 days of in-clinic and home use. Method: Each of the 57 enrolled type 1 diabetes mellitus and type 2 diabetes mellitus subjects wore 2 C-CGMs on the abdomen for 14 days. One part of the evaluation was the performance versus reference glucose values generated for 12 -hour in-clinic sessions on days 1, 4, 7, 10, and 14. Glucose blood samples were drawn every 15 minutes and analyzed with the Yellow Spring Instruments (YSI) 2300 glucose analyzer. The performance assessment on in-clinic days was based on paired YSI/CGM data points and on home-use days was based on paired fingerstick BGM (blood glucose monitoring)/CGM data points. Results: A total of 17 823 CGM/YSI data points during in-clinic use was analyzed. The mean absolute relative difference for glucose values between 100 and 400 mg/dL (MARD) and mean absolute difference for values between 40 and 100 mg/dL (MAD) were 11.5% and 15.1 mg/dL, respectively. The system accuracy during home use was 12.7% and 15 mg/dL for MARD and MAD, respectively. There were no serious adverse events or infectious complications reported. A modified algorithm “Hybrid Algorithm” was used in a prospective analysis of the in-clinic data, resulting in a MARD of 9.9% and MAD of 14.5 mg/dL. Conclusions: The performance of the C-CGM device over 14 days meets the safety and efficacy standards of CGM systems for managing blood glucose levels in people with diabetes. This was further confirmed when the C-CGM system was given approval for CE Mark in October 2019.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In recent years, a number of non-iCGM-approved CGM devices have entered the market outside the United States worldwide.”
From Importance of FDA-integrated continuous glucose monitors to ensure accuracy of continuous glucose monitoring (2025) · cites this paper as [20]
In the citing paper
“In contrast, the manufacturers of non-iCGM devices have not published accuracy data in these important settings or have not shown a documented probability of adequate sensor survival until the end of the claimed sensor life.20-23,36”
From Importance of FDA-integrated continuous glucose monitors to ensure accuracy of continuous glucose monitoring (2025) · cites this paper as [20]
In the citing paper
“Furthermore, the body of evidence is scarce, insufficient, or even lacking for many non-iCGM-approved entrants, in terms not only of accuracy, but also of glycemic outcomes (i.e., time in range, time above range, time below range, coefficient of variation).20-23,29”
From Importance of FDA-integrated continuous glucose monitors to ensure accuracy of continuous glucose monitoring (2025) · cites this paper as [20]
In the citing paper
“For example, publicly available accuracy data from both observational and randomized clinical trials supporting some non-iCGM-approved entrants include small sample sizes and/or very few data points in the critical range of <70 mg/dL, more stable patients, and no glucose and insulin challenges, and data may not have been published in peer-reviewed journals.8,11,20-24,35,36,39-48”
From Importance of FDA-integrated continuous glucose monitors to ensure accuracy of continuous glucose monitoring (2025) · cites this paper as [20]
In the citing paper
“By contrast, the manufacturers of many non-iCGM-approved devices sold outside the United States have not published robust accuracy data or randomized controlled trial data to support their use.”
From Importance of FDA-integrated continuous glucose monitors to ensure accuracy of continuous glucose monitoring (2025) · cites this paper as [20]
Citations
Cites
DRAIZE, J. H., WOODARD, G., & CALVERY, H. O. (1944) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)08751-8 · Cited by 2,602
Cappon, G., Vettoretti, M., Sparacino, G., & Facchinetti, A. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0121 · Cited by 477
Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes
Rodbard, D. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0035 · Cited by 458 · cited 4×
“396 Journal of Diabetes Science and Technology 16(2)”
BackgroundInfluentialAccuracy of a Fourth-Generation Subcutaneous Continuous Glucose Sensor
Christiansen, M. P., Garg, S. K., Brazg, R., Bode, B. W., Bailey, T. S., Slover, R. H., Sullivan, A., Huang, S., Shin, J., Lee, S. W., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0087 · Cited by 151
Engler, R., Routh, T. L., & Lucisano, J. Y. (2018) · Clinical Diabetes · doi:10.2337/cd17-0053 · Cited by 84
Role of Continuous Glucose Monitoring in Diabetes Treatment
Hirsch, I., Battelino, T., Peters, A., Chamberlain, J., Aleppo, G., & Bergenstal, R. (2018) · American Diabetes Association eBooks · doi:10.2337/db20181 · Cited by 73
Welsh, J. B., Gao, P., Derdzinski, M., Puhr, S., Johnson, T. K., Walker, T. C., & Graham, C. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0374 · Cited by 72
Pain assessment in humans — A reply to hall
Gracely, R. H., & Dubner, R. (1981) · Pain · doi:10.1016/0304-3959(81)90144-5 · Cited by 62
Christiansen, M. P., Klaff, L. J., Bailey, T. S., Brazg, R., Carlson, G., & Tweden, K. S. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0020 · Cited by 62
Karinka, S. A., Bailey, T. S., Brazg, R., Budiman, E. S., CASTORINO, K. N., Christiansen, M. P., Liljenquist, D. R., & Liu, H. (2019) · Diabetes · doi:10.2337/db19-910-p · Cited by 12
Research works printed but not linked: 5
- IDF Diabetes Atlas Eighth Edition 2017. Available at: https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html.
- Christiansen MP, 2019, DiabetesTechnolTher, 21, 231
- Rebec M, 2018, J Diabetes Sci Technol, 12, 426, 10.1177/1932296818761742 · DOI
- Rebec M, 2018, Diabetologia, 61, 1
- Draize JH, 1944, J Pharmacol Exp Ther, 82, 377
Cited by
Freckmann, G., Eichenlaub, M., Waldenmaier, D., Pleus, S., Wehrstedt, S., Haug, C., Witthauer, L., Jendle, J., Hinzmann, R., Thomas, A., et al. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231190941 · Cited by 86
“90,96,123,127,131,138,140,155,158,160 However, this cannot be recommended as the CGM value distribution is dependent on CGM accuracy and thus impairs the comparison of testing procedures among studies.”
BackgroundShang, T., Zhang, J. Y., Thomas, A., Arnold, M. A., Vetter, B. N., Heinemann, L., & Klonoff, D. C. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211007212 · Cited by 71
Approaches of wearable and implantable biosensor towards of developing in precision medicine
Ghazizadeh, E., Naseri, Z., Deigner, H.-P., Rahimi, H., & Altıntaş, Z. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1390634 · Cited by 89
Pemberton, J. S., Wilmot, E. G., Barnard‐Kelly, K., Leelarathna, L., Oliver, N., Randell, T., Taplin, C. E., Choudhary, P., & Adolfsson, P. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14962 · Cited by 44
“The performance of the GlucoMen Day using actual participant data achieves none of the standards.(24) However, after updating the algorithm and using generated data derived from original participant data,(55) the updated GlucoMen Day performance improved but failed to meet six of the seven performance standards.”
MethodKlonoff, D. C., Gabbay, M., Moon, S. J., & Wilmot, E. G. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241250357 · Cited by 36
Metadata
- Authors
- Rebec, M., Cai, K., Dutt-Ballerstadt, R., & Anderson, E.
- Affiliations
- Wilson Community College (US)
- WaveForm Diabetes, Inc., Salem, NH, USA
- WaveForm Diabetes, Inc., Wilsonville, OR, USA
- Corresponding author
- Rebec, Mihailo
- Venue
- Journal of Diabetes Science and Technology
- Publisher
- SAGE Publications
- Published
- 2020-10-21
- Volume
- 16
- Issue
- 2
- Pages
- 390-396
- ISSN
- 1932-2968 (ISSN-L)
- PMC
- PMC8861779
- OpenAlex
- W3093629784
- Cited by
- 11
- References
- 11
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 1 · 2021: 2
- FWCI
- 0.94
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Diabetes Science and Technology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- continuous glucose monitoring, type 1 diabetes, type 2 diabetes, device accuracy, mean absolute relative difference, home blood glucose monitoring, hybrid algorithm
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Humans, Blood Glucose Self-Monitoring, Reproducibility of Results
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Prospective Multicenter Clinical Performance Evaluation of the C-CGM System. https://app.cochat.ai/papers/10.1177/1932296820964574
- The paper
- Rebec, M., Cai, K., Dutt-Ballerstadt, R., & Anderson, E. (2022). A Prospective Multicenter Clinical Performance Evaluation of the C-CGM System. Journal of Diabetes Science and Technology. https://doi.org/10.1177/1932296820964574
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.